Merck KGaA: Stimuvax Clinical Program Temporarily Suspended
A patient participating in a Phase II exploratory clinical trial with the therapeutic cancer vaccine in patients with multiple myeloma developed encephalitis. The patient was randomized to an experimental arm of Stimuvax in combination with an intensified schedule of low-dose cyclophosphamide, which is not used in the other Stimuvax studies.
Effective immediately, the company has temporarily suspended recruitment into and treatment of patients already enrolled into the recruiting Stimuvax clinical trials. This action is a precautionary measure while the company is diligently investigating the cause of this adverse event.
The Phase III clinical program, consisting of the non-small cell lung cancer (NSCLC) studies START and INSPIRE and the breast cancer study STRIDE, is impacted as well as the other recruiting studies.
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.